Companies /Healthcare

Co-Diagnostics Inc

NASDAQ: CODX Medical Devices
$0.22
▼ $0.03 (−13.03%) today
Markets closed · 8:24pm ET

CODX at a Glance

Valuation
Market cap
$2.7M
Profitability
Revenue (TTM)
$858,890
EPS (TTM)
$-21.71
Price
52-week range
$0 – $14
Street target
$4.00

Headquartered in Salt Lake City, UT Fiscal year ends December NASDAQ: CODX co-dx.com

About Co-Diagnostics

Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company built on a patented Co-Primers technology for designing tests that detect and analyze nucleic acids (DNA or RNA).

- **Current sales:** Revenue comes from product sales. This includes the Vector Smart laboratory equipment, consumables and reagents used for mosquito pool PCR surveillance. Vector Smart serves customers across 21 U.S. states and was recently deployed internationally at a U.S. Air Force base.
- **Pipeline platform:** The company's main development focus is the Co-Dx PCR at-home and point-of-care platform, which includes the PCR Home and PCR Pro instruments, a mobile app and associated tests. The platform is not yet available for sale.
- **Regulatory filings:** A Flu A/B & RSV test is under FDA 510(k) and CLIA waiver review. A point-of-care tuberculosis test (CoSara PCR MTB) is under review by India's CDSCO through CoSara Diagnostics, a joint venture.
- **Other development work:** The company is developing Ebola and Bundibugyo virus assays, including plasma-based testing in collaboration with ReadyGo Diagnostics. It has also launched cloud and mobile data infrastructure in India.
- **Partners:** It works with joint ventures and partners such as CoSara and CoMira on manufacturing and international commercialization. Updated

CODX Coverage

7:31am ET
Health and Healthcare

Aytu BioScience Stock: Developments in Denver

Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.

Chris Lange

Frequently Asked Questions

What does Co-Diagnostics do?

Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company built on a patented Co-Primers technology for designing tests that detect and analyze nucleic acids (DNA or RNA). - **Current sales:** Revenue comes from product sales.

What is the CODX stock price target?

The Wall Street consensus 12-month price target for CODX is $4.00.